113 related articles for article (PubMed ID: 25178559)
1. Growth differentiation factor GDF-15 does not influence iron metabolism in stable chronic haemodialysis patients.
Li XY; Ying J; Li JH; Zhu SL; Li J; Pai P
Ann Clin Biochem; 2015 May; 52(Pt 3):399-403. PubMed ID: 25178559
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa.
Nalado AM; Olorunfemi G; Dix-Peek T; Dickens C; Khambule L; Snyman T; Paget G; Mahlangu J; Duarte R; George J; Naicker S
BMC Nephrol; 2020 Sep; 21(1):415. PubMed ID: 32993549
[TBL] [Abstract][Full Text] [Related]
3. Regulation of hepcidin through GDF-15 in cancer-related anemia.
Jiang F; Yu WJ; Wang XH; Tang YT; Guo L; Jiao XY
Clin Chim Acta; 2014 Jan; 428():14-9. PubMed ID: 24384540
[TBL] [Abstract][Full Text] [Related]
4. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients.
Lukaszyk E; Lukaszyk M; Koc-Zorawska E; Bodzenta-Lukaszyk A; Malyszko J
Int Urol Nephrol; 2016 Jun; 48(6):839-44. PubMed ID: 27043030
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor 15 increased in severe aplastic anemia patients.
Shao Y; Wang H; Liu C; Cao Q; Fu R; Wang H; Wang T; Qi W; Shao Z
Hematology; 2017 Oct; 22(9):548-553. PubMed ID: 28385068
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.
Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF
Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871
[TBL] [Abstract][Full Text] [Related]
7. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
9. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease.
Łukaszyk E; Łukaszyk M; Koc-Żórawska E; Tobolczyk J; Bodzenta-Łukaszyk A; Małyszko J
Kidney Blood Press Res; 2015; 40(4):366-73. PubMed ID: 26160488
[TBL] [Abstract][Full Text] [Related]
10. GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance.
Yalcin MM; Altinova AE; Akturk M; Gulbahar O; Arslan E; Ors Sendogan D; Yetkin I; Toruner FB
J Diabetes Res; 2016; 2016():1240843. PubMed ID: 27642607
[TBL] [Abstract][Full Text] [Related]
11. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
Zipperer E; Post JG; Herkert M; Kündgen A; Fox F; Haas R; Gattermann N; Germing U
Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
13. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.
Farag NM; Mousa M; Elsayed E; Ismeil A
Ital J Pediatr; 2023 Aug; 49(1):106. PubMed ID: 37649102
[TBL] [Abstract][Full Text] [Related]
14. The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study.
Aydin Z; Gursu M; Karadag S; Uzun S; Sumnu A; Doventas Y; Ozturk S; Kazancioglu R
Ren Fail; 2014 Sep; 36(8):1253-7. PubMed ID: 25040737
[TBL] [Abstract][Full Text] [Related]
15. The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/β
Larissi K; Politou M; Margeli A; Poziopoulos C; Flevari P; Terpos E; Papassotiriou I; Voskaridou E
Blood Cells Mol Dis; 2019 Jul; 77():137-141. PubMed ID: 31071550
[TBL] [Abstract][Full Text] [Related]
16. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
17. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.
Finkenstedt A; Bianchi P; Theurl I; Vogel W; Witcher DR; Wroblewski VJ; Murphy AT; Zanella A; Zoller H
Br J Haematol; 2009 Mar; 144(5):789-93. PubMed ID: 19120353
[TBL] [Abstract][Full Text] [Related]
18. Study of growth differentiation factor-15 in polytransfused children with β-thalassemia.
Meena S; Sharma K; Sharma S; Chandra J
Indian J Pathol Microbiol; 2023; 66(1):81-84. PubMed ID: 36656215
[TBL] [Abstract][Full Text] [Related]
19. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
20. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
